Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

International Journal of Clinical Oncology

Volumn 19, Issue 4, 2014, Pages 594-600

  Keam, Bhumsuk ^a,b   Kim, Dong Wan ^a,b   Park, Jin Hyun ^a   Lee, Jeong Ok ^a   Kim, Tae Min ^a,b   Lee, Se Hoon ^a,b   Chung, Doo Hyun ^a   Heo, Dae Seog ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Complex mutation; EGFR; Erlotinib; Gefitinib; Rare mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COMPLEX MUTATION; CONTROLLED STUDY; DRUG EFFICACY; EGFR GENE; EXON; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RARE MUTATION; SEQUENCE ANALYSIS; SMALL CELL CARCINOMA; SMOKING; TREATMENT RESPONSE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84906350720     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0602-1     Document Type: Article

References (26)

1. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500 (Pubitemid 38720929)
2. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139 (Pubitemid 38637993)
3. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or car-boplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957
4. Han SW, Kim TY, Hwang PG et al (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501
5. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311 (Pubitemid 39209661)
6. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-128
7. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388
8. Wu JY, Yu CJ, Chang YC et al (2011) Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17:3812-3821
9. Pallis AG, Voutsina A, Kalikaki A et al (2007) 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 97:1560-1566 (Pubitemid 350175853)
10. Murray S, Dahabreh IJ, Linardou H et al (2008) Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 3:832-839
11. Gu D, Scaringe WA, Li K et al (2007) Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 28:760-770 (Pubitemid 47282437)
12. De Pas T, Toffalorio F, Manzotti M et al (2011) Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 6:1895-1901
13. Ma F, Sun T, Shi Y et al (2009) Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 66:114-119
14. Centeno I, Blay P, Santamaria I et al (2011) Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma. BMC Cancer 11:172
15. Yun CH, Mengwasser KE, Toms AV et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105:2070-2075 (Pubitemid 351439466)
16. Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932-20937
17. Zhang GC, Lin JY, Wang Z et al (2007) Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin Oncol (R Coll Radiol) 19:499-506 (Pubitemid 47181182)
18. Huang SF, Liu HP, Li LH et al (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-8203
19. Hsieh MH, Fang YF, Chang WC et al (2006) Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 53:311-322
20. Hata A, Yoshioka H, Fujita S et al (2010) Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer. J Thorac Oncol 5:1524-1528
21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
22. Kim YT, Kim TY, Lee DS et al (2008) Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 59:111-118
23. Wu JY, Wu SG, Yang CH et al (2008) Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 14:4877-4882
24. Yokoyama T, Kondo M, Goto Y et al (2006) EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 97:753-759 (Pubitemid 43983788)
25. Wu SG, Chang YL, Hsu YC et al (2008) Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist 13:1276-1284
26. Su KY, Chen HY, Li KC et al (2012) Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30:433-440